SCLC
Study Defines SCLC Subtypes With Distinct Therapeutic Vulnerabilities
Countering the one-size-fits-all treatment for small-cell lung cancer, investigators classified the malignancy into ...
FEBRUARY 2, 2021
FDA Approves Zepzelca as New Option for Metastatic SCLC
The FDA granted accelerated approval to lurbinectedin (Zepzelca, Pharma Mar/Jazz) to treat adults with metastatic ...
JUNE 18, 2020
FDA Approves Cyramza Plus Erlotinib for EGFR-Mutated Metastatic NSCLC
The FDA approved the use of ramucirumab (Cyramza, Lilly) in combination with erlotinib for first-line treatment of ...
JUNE 3, 2020
Imfinzi Approved for First-Line Treatment of Extensive-Stage SCLC
The FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with etoposide and either carboplatin or ...
APRIL 6, 2020
Keytruda Gains Approval for Treatment of SCLC
The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment of patients who have ...
JUNE 20, 2019
FDA Approves Opdivo as Third-Line Rx for SCLC
The FDA granted accelerated approval to nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients with ...
AUGUST 21, 2018
Statins Do Not Benefit Patients With Lung Cancer
It was initially thought that lowering cholesterol levels could impair the development and growth of cancer cells, ...
FEBRUARY 28, 2017
